Grünenthal and Mesoblast entered into a partnership to develop a biologics-based treatment for chronic lower back pain.
NervGen Pharma is planning its clinical development strategy for its compound, NVG-291, in spinal cord injury and multiple sclerosis patients.
Duchenne UK awarded researchers from Minneapolis-based University of Minnesota Medical School $945,000 to advance their work around a stem cell-based therapy to treat Duchenne muscular dystrophy.
Ortho Regenerative Technologies reported a successful pre-investigational drug meeting with the FDA in February and is now preparing for its rotator cuff phase I/II clinical trial.
More articles on practice management:
Stryker adds to spine division with $550M acquisition: 3 details
New York spine surgeon pleads guilty to illegal painkiller prescription, faces $250K fine
15 spine, neurosurgeon moves in August
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
